Abstract We investigated the influence of the HIV infection on serum paraoxonase-3 (PON3) concentration, and assessed the relationships with lipoprotein-associated abnormalities, immunological response, and accelerated atherosclerosis. We studied 207 HIV-infected patients and 385 healthy volunteers. Serum PON3 was determined by in-house ELISA and PON3 distribution in lipoproteins was investigated by FPLC. Polymorphisms of the PON3 promoter were analyzed by the Iplex Gold MassArray TM method. PON3
normalization of vascular endothelium function (12-15). Moreover, recent studies showed that PON2 expression is increased in cultured hematopoietic cells and mouse thymocytes after HIV-1 infection (16). The PON family also plays a role in innate immunity and can prevent bacterial infection (17).
Although knowledge on PON1 and PON2 structure and function is rapidly expanding, data about the PON3 protein remain elusive. Its gene was identified in 1996 when Primo-Parmo et al. (7) detected a large number of cDNA sequences in the Genome Data Base with significant similarity to, but not identical with, human PON1. The percentage identity among human PON1, PON2, and PON3 genes is high (about 70%) and the genes are believed to derive from a common precursor (11). Clinical research on PON3 has been hampered by the lack of methods for measurement, but we recently described a high-throughput, reliable enzyme-linked immunosorbent assay (ELISA) to analyze PON3 concentration in human serum (18). The main objective of the present study was to investigate whether serum PON3 concentration may provide new information to improve our understanding of metabolic complications associated with HIV infection.
MATERIALS AND METHODS

Study participants
From among the HIV-infected patients attending our clinic, 207 (139 men, 68 women; mean age 38 years; range 22 to 66) accepted an invitation to participate in the present study. Of these patients, 122 were co-infected by the hepatitis C virus (HCV). All patients were undergoing antiretroviral therapy with protease inhibitors (PI) or with non-nucleoside reverse transcriptase inhibitors who participated in an ongoing epidemiological study being conducted in our geographical area, and the details of which have been previously reported (21).
All the volunteers had been invited to attend a clinical examination and to provide a fasting blood sample. There was no clinical or analytical evidence of renal insufficiency, liver damage, neoplasia, or neurological disorders.
A fasting venous blood sample was obtained from all the participants. CD4+ T-cells and CD8+ T-cells were analyzed immediately, and serum, plasma and leukocytes were stored at −80ºC in our biological sample bank until the other measurements were performed. We employed independent aliquots that were never thawed before this investigation, although participants in this study partially coincided with those reported in previous investigations (5, 6). All the participants provided fully-informed consent to participation in the study on the understanding that anonymity of all data is guaranteed. The study was approved by the Hospital Universitari de Sant Joan de Reus Institutional Review Board.
Biochemical and serological measurements
Serum PON3 concentrations were determined by in-house ELISA using rabbit polyclonal antibodies generated against a synthetic peptide with a sequence specific to mature PON3. Details of this method have been previously 
FPLC lipoprotein fractionation
PON3 distribution in lipoproteins was assessed by FPLC (Bio-Rad BioLogic DuoFlow 10 system, Bio-Rad Laboratories, Inc. Hercules, CA). Sera from 3 HIV-infected patients and 3 non-infected participants were pooled separately. To maximize the possible differences between groups, sera from the HIV-infected patients were chosen to have a PON3 concentration > 20 mg/l. Two-hundred µl from each pool were injected into a Superose 6/300 GL column (GE Healthcare Europe GmbH, Glattbrugg, Switzerland), and five-hundred µl fractions were collected. Cholesterol, triglycerides and PON3 in each fraction were measured as described.
PON3 promoter genotyping
Genomic DNA was obtained from leukocytes (Puregene DNA Isolation reagent set, Gentra Systems Inc., Minneapolis, MN, USA). Selected single nucleotide polymorphisms (SNPs) of the PON3 promoter were analyzed by the Iplex Gold MassArray TM method (Sequenom Inc., San Diego, CA, USA) at the Spanish National Genotyping Center (Centro Nacional de Genotipado, Universitat Pompeu Fabra, Barcelona, Spain).
Statistical analysis
The normality of distributions was determined with the KolmogorovSmirnov test. Differences between two groups were assessed with the Student's t-test (parametric) or the Mann-Whitney U test (non-parametric).
Differences between multiple groups were analyzed by the Kruskal-Wallis test.
Pearson or Spearman correlation coefficients were used to evaluate the degree of association between variables. Each SNP was tested for Hardy-Weinberg Table 2 ).
FPLC lipoprotein fractionation
In non-infected participants, PON3 immunoreactivity was observed almost exclusively in HDL fractions. However, in the HIV-infected pool, a substantial amount of this protein eluted with the smallest HDL, and with LDL particles (Fig. 2) .
Influence of genotype on serum PON3 concentrations
The frequency distributions of the selected PON3 promoter gene polymorphisms are shown in Table 2 . There were no significant differences between control subjects and HIV-infected patients. These polymorphisms moderately influenced serum PON3 concentrations in the control subjects, but not in the patient group.
All PON3 promoter polymorphisms were strongly linked in a single haplotype, and we did not observe any significant differences between patients and controls ( Supplementary Fig. 1 ).
Relationships among serum PON3 concentrations and the immunological and virological outcomes
Co-infection with HCV was associated with a significantly higher PON3 concentration [5.8 (2.6 − 11.1) vs. 4.5 (2.4 − 11.6) mg/l, respectively; P = 0.024].
There were not any significant associations between serum PON3
concentrations and CD4+T and CD8+T cell counts, the CD4+/CD8+ ratio or the plasma HIV-1 viral load (Supplementary Table 3 ). There was a significant direct linear relationship (r = 0.397; P < 0.001) between serum PON3 and β-2-microglobulin concentrations (Fig. 3A) . There were no significant differences in 
Influence of treatments on serum PON3 concentrations
We observed a significant inverse relationship between serum PON3
concentrations and the duration of the antiretroviral therapy in patients under NNRTI-based scheme (r = -0.250; P = 0.035; Fig. 3B ), but not in patients receiving a PI-based scheme (r = -0.059; P = 0.408).
PON3 and sub-clinical atherosclerosis
When patients were classified according to the presence (n = 137) or absence (n = 41) of sub-clinical atherosclerosis , no significant differences in serum PON3 concentrations were found [5.2 (2.5 − 11.2) vs. 5.4 (2.5 − 11.1) mg/l, respectively; P = 0.959]. Furthermore, there was no significant association between serum PON3 concentration and the quantitative value of the IMT (r = 0.047; P = 0.544).
Multivariate analysis for PON3 concentration in HIV-infected patients
A multiple linear regression analysis showed significant and independent relationships of serum PON3 concentrations with oxidized LDL and with the use of NNRTI as the backbone of the antiretroviral therapy (Table 3) We did not find any significant differences in genotype or haplotype of PON3 promoter gene polymorphisms between patients and controls, suggesting that genotype does not influence the course of the disease. In our previous report, we observed a moderate influence of some polymorphisms on serum PON3 concentration in the general population (18), but this is not the case in HIV-infected patients. Possibly, the up-regulation of PON3 expression secondary to the infection masks the small effect of these polymorphisms.
Unlike PON1 (6), PON3 seems not to be associated with the presence of sub-clinical atherosclerosis is HIV-infected patients. Although lipid peroxidation and atherosclerosis are known to be strongly linked phenomena (39), the pathophysiology of atherosclerosis is complex, and our results suggest that the protective effects of these enzymes differs under certain situations. Perhaps PON1 is more efficient in protecting against the alterations leading to atherosclerosis and PON3 is in some way involved in protection against infection. This is, to the best of our knowledge, the first in vivo evidence suggesting such a hypothesis, and warrants further investigation. Another In conclusion, the present study reports for the first time an important increase in serum PON3 concentrations in HIV-infected patients which is associated with their oxidative status and that could be partially attenuated by the treatment with some antiretroviral agents. Long-term, prospective studies are needed to further confirm the possible influence of this enzyme on the course of this disease and its possible utility as an analytical biomarker. Results are presented as means and SD in parentheses (parametric) or as medians and 95% CI in parenthesis (nonparametric). 
